KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Scotts Miracle-Gro (SMG) EBITDA (2016 - 2025)

Historic EBITDA for Scotts Miracle-Gro (SMG) over the last 17 years, with Q4 2025 value amounting to -$21.8 million.

  • Scotts Miracle-Gro's EBITDA rose 5240.17% to -$21.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $387.8 million, marking a year-over-year increase of 8440.32%. This contributed to the annual value of $358.6 million for FY2025, which is 7174.33% up from last year.
  • According to the latest figures from Q4 2025, Scotts Miracle-Gro's EBITDA is -$21.8 million, which was up 5240.17% from -$150.1 million recorded in Q3 2025.
  • Over the past 5 years, Scotts Miracle-Gro's EBITDA peaked at $424.1 million during Q2 2021, and registered a low of -$562.5 million during Q3 2022.
  • In the last 5 years, Scotts Miracle-Gro's EBITDA had a median value of -$21.8 million in 2025 and averaged $31.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 50188.17% in 2022, then skyrocketed by 15886.16% in 2024.
  • Scotts Miracle-Gro's EBITDA (Quarter) stood at -$37.2 million in 2021, then fell by 12.37% to -$41.8 million in 2022, then fell by 13.16% to -$47.3 million in 2023, then increased by 3.17% to -$45.8 million in 2024, then soared by 52.4% to -$21.8 million in 2025.
  • Its EBITDA stands at -$21.8 million for Q4 2025, versus -$150.1 million for Q3 2025 and $215.0 million for Q2 2025.